Roche hit with an­oth­er key R&D set­back as oral SERD flops in breast can­cer

Roche’s oral SERD giredestrant has flunked a Phase II study for ad­vanced breast can­cer, rais­ing fresh ques­tions about the fu­ture of the field as well as the phar­ma gi­ant’s late-stage pipeline.

Al­ready sin­gled out as a top prospect in piv­otal tri­als, Roche re­vealed the set­back in its Q1 re­lease Mon­day. In­ves­ti­ga­tors flagged a fail­ure on the pri­ma­ry end­point for progress-free sur­vival among ER-pos­i­tive, HER2-neg­a­tive pa­tients in the acel­ERA tri­al, then not­ed that “ef­fi­ca­cy da­ta were en­cour­ag­ing with a more pro­nounced ben­e­fit in pa­tients with high­er de­pen­dence on es­tro­gen re­cep­tor ac­tiv­i­ty.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER